Tyra Biosciences (TYRA)
(Delayed Data from NSDQ)
$22.04 USD
+0.46 (2.13%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $22.05 +0.01 (0.05%) 7:58 PM ET
2-Buy of 5 2
C Value D Growth A Momentum C VGM
Income Statements
Fiscal Year end for Tyra Biosciences, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | NA |
Cost Of Goods | 0 | 0 | 0 | 0 | NA |
Gross Profit | 0 | 0 | 0 | 0 | NA |
Selling & Adminstrative & Depr. & Amort Expenses | 80 | 59 | 26 | 9 | 0 |
Income After Depreciation & Amortization | -80 | -59 | -26 | -9 | 0 |
Non-Operating Income | 11 | 4 | 0 | 0 | NA |
Interest Expense | 0 | 0 | 0 | 0 | NA |
Pretax Income | -69 | -55 | -26 | -9 | NA |
Income Taxes | 0 | 0 | 0 | 0 | NA |
Minority Interest | 0 | 0 | 0 | 0 | NA |
Investment Gains/Losses | 0 | 0 | 0 | 0 | NA |
Other Income/Charges | 0 | 0 | 0 | 0 | NA |
Income From Cont. Operations | -69 | -55 | -26 | -9 | NA |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | NA |
Net Income (GAAP) | -69 | -55 | -26 | -9 | NA |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -80 | -59 | -26 | -9 | 0 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | NA |
Income After Depreciation & Amortization | -80 | -59 | -26 | -9 | 0 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 42.71 | 41.88 | 13.78 | NA | NA |
Diluted EPS Before Non-Recurring Items | -1.62 | -1.32 | -1.91 | NA | NA |
Diluted Net EPS (GAAP) | -1.62 | -1.32 | -1.91 | NA | NA |
Fiscal Year end for Tyra Biosciences, Inc falls in the month of December .
All items in Millions except EPS data.
9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 23.54 | 22.32 | 25.64 | 23.96 | 16.01 |
Income After SG&A, R&D, and Dept/Amort Expenses | -23.54 | -22.32 | -25.64 | -23.96 | -16.01 |
Non-Operating Income | 4.83 | 4.13 | 2.80 | 2.81 | 2.74 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -18.70 | -18.19 | -22.83 | -21.15 | -13.27 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -18.70 | -18.19 | -22.83 | -21.15 | -13.27 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -18.70 | -18.19 | -22.83 | -21.15 | -13.27 |
Earnings Per Share Data | 9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 |
---|---|---|---|---|---|
Average Shares | 58.67 | 52.23 | 42.97 | 42.87 | 42.59 |
Diluted EPS Before Non-Recurring Items | -0.32 | -0.35 | -0.53 | -0.49 | -0.31 |
Diluted Net EPS (GAAP) | -0.32 | -0.35 | -0.54 | -0.49 | -0.31 |